NeuroDerm Ltd. Report issue

For profit Phase 2 Phase 3
Founded: Rehovot Israel (2003)
Status: Acquired by Mitsubishi Tanabe (2017)

Organization Overview

First Clinical Trial
2010
NCT01103011
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NeuroDerm Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

carbidopa (sinemet) (13 trials)

levodopa (larodopa) (11 trials)

Drugs in Phase 2 Trials (2)

nd0801 (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 2)

Hyperkinesis (Phase 2)

Parkinson Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 4